Click main image to view in full screen.
Pharma Disease Insight: Colorectal Cancer (PowerPoint PPTX Slide Deck)
PowerPoint (PPTX) 28 Slides
ONCOLOGY PPT DESCRIPTION
Colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025 in the seven major pharmaceutical markets under study. Growth will be fueled by continued uptake of premium-priced therapies and the approval of six emerging therapies. In 2025, immune checkpoint inhibitors will hold an impressive 33% share of this market.
Two immune checkpoint inhibitors are expected to launch for colorectal cancer (Merck & Co.'s Keytruda [pembrolizumab] and Roche/Genentech/Chugai's Tecentriq [atezolizumab]), significantly contributing to the aforementioned market growth. Their combined major-market sales will total approximately $4.2 billion in 2025, driven largely by the two agents' approval in MSI-H and dMMR patient populations.
INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market
Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.
Source: Best Practices in Oncology PowerPoint Slides: Pharma Disease Insight: Colorectal Cancer PowerPoint (PPTX) Presentation Slide Deck, BigPharma2000
